Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - iron polymaltose -

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ferric carboxymaltose -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - ferric carboxymaltose, quantity: 1800 mg (equivalent: iron, qty 500 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ferinject is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used ? there is a clinical need to deliver iron rapidly,the diagnosis of iron deficiency must be based on laboratory tests.,ferinject is indicated for the treatment of iron deficiency anaemia in children aged 1 to 13 years when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used,the diagnosis of iron deficiency anaemia must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - ferric carboxymaltose, quantity: 360 mg (equivalent: iron, qty 100 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ferinject is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used ? there is a clinical need to deliver iron rapidly,the diagnosis of iron deficiency must be based on laboratory tests.,ferinject is indicated for the treatment of iron deficiency anaemia in children aged 1 to 13 years when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used,the diagnosis of iron deficiency anaemia must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - ferric carboxymaltose, quantity: 3.6 g (equivalent: iron, qty 1000 mg) - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - ferinject is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used ? there is a clinical need to deliver iron rapidly,the diagnosis of iron deficiency must be based on laboratory tests.,ferinject is indicated for the treatment of iron deficiency anaemia in children aged 1 to 13 years when:,? oral iron preparations are ineffective ? oral iron preparations cannot be used,the diagnosis of iron deficiency anaemia must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 185 mg/ml (equivalent: iron, qty 50 mg/ml) - oral liquid - excipient ingredients: sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; purified water; sucrose; sodium hydroxide; flavour - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.,prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 37 mg/ml (equivalent: iron, qty 10 mg/ml) - oral liquid - excipient ingredients: propyl hydroxybenzoate; purified water; sorbitol solution (70 per cent) (non-crystallising); ethanol; sucrose; sodium hydroxide; methyl hydroxybenzoate; flavour - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 370 mg (equivalent: iron, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 6000; crospovidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - iron sucrose, quantity: 540 mg/ml (equivalent: iron, qty 20 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - venofer is indicated for the treatment of iron deficiency anaemia in patients undergoing chronic haemodialysis and who are receiving supplemental erythropoietin therapy.,the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. serum ferritin, serum iron, transferrin saturation and hypochromic red cells).